Lactobacillus breuis OK56 ameliorates high-fat diet-induced obesity in mice by inhibiting NF-kappa B activation and gut microbial LPS production

摘要

The anti-obesity effects of anti-inflammatory probiotics, isolated Lactobacillus brevis OK56 from the kimchi lactic acid bacteria collection, were examined and its effects on high-fat diet (HFD)-induced obesity (DIO) mice were evaluated. OK56 strongly inhibited NF-kappa B activation and TNF-alpha, IL-1 beta, and IL-6 expression in lipopolysaccharide (LPS)-stimulated macrophages. Oral administration of OK56 (1 x 10(9) CPU/mouse) suppressed the HFD-induced increase in body and epididymal fat weight gains (by 28 and 31%, respectively), as well as plasmatic atherogenic index, and LPS level. Real-time PCR analysis revealed that OK56 also inhibited HFD-induced expression of F4/80, CD68, CD204,TNF-alpha, and IL-1 beta in the adipose tissue of DIO mice. OK56 abrogated the HFD-induced disturbance to gut microbiota, such as the reduction in the number of bifidobacteria, the increase in the colonic fluid LPS, and the increase in the breath H-2 levels. OK56 also inhibited HFD-induced expression of inducible NO synthetase (iNOS) and cyclooxygenase (COX)-2 and the activation of nuclear factor (NF)-kappa B in the colon. Furthermore, OK56 inhibited HFD-reduced expression of tight junction proteins ZO-1, occludin and claudin-1. These results suggest that OK56 has anti-obesity, which exerts through the inhibition of gut microbiota LPS production, colonic NF-kappa B signaling pathway, and macrophage infiltration into the adipose tissue. (C) 2014 Elsevier Ltd. All rights reserved.